Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice

Brain Research

Volumn 1279, Issue , 2009, Pages 121-130

  Guo, Qingmin ^a   Wang, Guangming ^a   Liu, Xiaowei ^a   Namura, Shobu ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Aorta; Brain; eNOS; Fibrate; Focal ischemia; MCAO; Mouse; PPAR

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN INFARCTION SIZE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; GENE EXPRESSION; IMAGING; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; SWELLING;

ANIMALS; ANTILIPEMIC AGENTS; AORTA; BODY TEMPERATURE; BRAIN; CEREBROVASCULAR CIRCULATION; CHOLESTEROL; GEMFIBROZIL; GENE EXPRESSION; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIGLYCERIDES;

ANIMALIA; MUS;

EID: 67649414212     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.04.055     Document Type: Article

References (30)

1. Arsenijevic D., de Bilbao F., Plamondon J., Paradis E., Vallet P., Richard D., Langhans W., and Giannakopoulos P. Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J. Cereb. Blood Flow Metab. 26 3 (2006) 433-445
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., and Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 3 (1986) 472-476
3. Bloomfield H.E. The role of fibrates in a statin world. Arch. Intern. Med. 166 7 (2006) 715-716
4. Bloomfield Rubins H., Davenport J., Babikian V., Brass L.M., Collins D., Wexler L., Wagner S., Papademetriou V., Rutan G., Robins S.J., and VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103 23 (2001) 2828-2833
5. Bordet R., Ouk T., Petrault O., Gele P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B., Fruchart J.C., and Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 34 Pt. 6 (2006) 1341-1346
6. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49 10 (2000) 497-505
7. Cuzzocrea S., Di Paola R., Mazzon E., Genovese T., Muià C., and Caputi A.P. WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock 22 4 (2004) 340-346
8. Deplanque D., Gele P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.C., Cecchelli R., Staels B., Duriez P., and Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23 15 (2003) 6264-6271
9. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., and Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 95 15 (1998) 8880-8885
10. Escher P., and Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448 2 (2000) 121-138
11. Forrester K.R., Stewart C., Tulip J., Leonard C., and Bray R.C. Comparison of laser speckle and laser Doppler perfusion imaging: measurement in human skin and rabbit articular tissue. Med. Biol. Eng. Comput. 40 6 (2002) 687-697
12. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1996), Academic Press, London
13. Gerlai R., Thibodeaux H., Palmer J.T., van Lookeren Campagne M., and Van Bruggen N. Transient focal cerebral ischemia induces sensorimotor deficits in mice. Behav. Brain Res. 108 1 (2000) 63-71
14. Heneka M.T., and Landreth G.E. PPARs in the brain. Biochim. Biophys. Acta 1771 8 (2007) 1031-1045
15. Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., and Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 352 3 (2003) 203-206
16. Iwashita A., Muramatsu Y., Yamazaki T., Muramoto M., Kita Y., Yamazaki S., Mihara K., Moriguchi A., and Matsuoka N. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J. Pharmacol. Exp. Ther. 320 (2007) 1087-1096
17. Jones B.J., and Roberts D.J. A rotarod suitable for quantitative measurements of motor incoordination in naive mice. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 259 2 (1968) 211
18. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesäniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M., and FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 9500 (2005) 1849-1861
19. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172 9 (2004) 5790-5798
20. Matsuura K., Kabuto H., Makino H., and Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73 1 (1997) 45-48
21. Namura S., Iihara K., Takami S., Nagata I., Kikuchi H., Matsushita K., Moskowitz M.A., Bonventre J.V., and Alessandrini A. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A. 98 20 (2001) 11569-11574
22. Ospina J.A., Krause D.N., and Duckles S.P. 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 33 2 (2002) 600-605
23. Royl G., Balkaya M., Lehmann S., Lehnardt S., Stohlmann K., Lindauer U., Endres M., Dirnagl U., and Meisel A. Effects of the PDE5-inhibitor vardenafil in a mouse stroke model. Brain Res. 1265 (2009) 148-157
24. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., and Greenberg J.H. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 2 (2005) 353-359
25. Sivarajah A., Chatterjee P.K., Hattori Y., Brown P.A., Stewart K.N., Todorovic Z., Mota-Filipe H., and Thiemermann C. Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med. Sci. Monit. 8 12 (2002) BR532-BR539
26. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 6687 (1998) 790-793
27. Von Knethen A.A., and Brune B. Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages. FASEB J. 15 2 (2001) 535-544
28. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P.K., and Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 16 9 (2002) 1027-1040
29. Yue T.L., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., Lysko P.G., Gu J.L., Boyce R., Zimmerman D.M., Hart T.K., Buckingham R.E., and Ohlstein E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-g agonist rosiglitazone. Circulation 104 21 (2001) 2588-2594
30. Zhao Y., Patzer A., Gohlke P., Herdegen T., and Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22 1 (2005) 278-282